What is the treatment for molluscum contagiosum in immunocompetent and immunocompromised individuals?

Treatment of Molluscum Contagiosum

Immunocompetent Patients

Physical removal methods—including curettage, simple excision, excision with cautery, or cryotherapy—are the first-line treatment for molluscum contagiosum in immunocompetent individuals, particularly when lesions are symptomatic, multiple, or located near the eyes. 1, 2

Treatment Algorithm for Immunocompetent Patients

Active Treatment Indications:

• Symptomatic lesions (painful, itchy, or inflamed) 1
• Multiple lesions that increase risk of autoinoculation and transmission 1, 2
• Periocular lesions causing associated conjunctivitis 1, 2
• Genital lesions in adults to reduce sexual transmission risk 3

Watchful Waiting is Reasonable for:

• Asymptomatic lesions 4
• Limited number of lesions 4
• No periocular involvement 4
• Lesions typically resolve spontaneously in 6-12 months, though can persist up to 4-5 years 1, 4

Specific Treatment Modalities

Physical Removal Methods (First-Line):

• Cryotherapy with liquid nitrogen achieves complete response in approximately 93% of cases 1, 4
• Curettage, simple excision, or excision with cautery are equally effective options 1, 2
• Important caveat: Cryotherapy carries higher risk of postinflammatory hyperpigmentation (may persist 6-12 months) or scarring, particularly concerning for facial lesions or darker skin tones 1, 4
• Avoid cryotherapy on sensitive areas including eyelids, lips, nose, and ears due to higher complication risk 1

Chemical Treatments (Alternative First-Line):

• 10% potassium hydroxide solution has similar efficacy to cryotherapy (86.6% vs 93.3% complete response) with better cosmetic results due to lower hyperpigmentation risk 1, 4
• Cantharidin shows effectiveness in observational studies, though randomized controlled trial evidence is limited 1

Critical Treatment Principle:

• Identify and treat ALL lesions, including nascent ones, during the initial treatment session to reduce recurrence risk 1, 2
• Reducing viral load allows the host immune response to eliminate residual virus 1, 2

Treatments to AVOID

Imiquimod is NOT effective and should NOT be used for molluscum contagiosum—it showed no benefit compared to placebo in randomized controlled trials in both children and adults. 1, 4, 5

Special Considerations for Periocular Lesions

• Physical removal is mandatory for lesions on or near eyelids with associated conjunctivitis 1, 2
• Conjunctivitis may require several weeks to resolve after lesion elimination 1, 2
• Monitor for resolution of conjunctivitis at follow-up 1

Pediatric-Specific Considerations

• Salicylic acid is contraindicated in children under 2 years due to systemic toxicity risk 4
• Physical removal methods remain first-line, though may be frightening to children 6
• Hand hygiene (alcohol-based disinfectant or soap and water) is the most important prevention method 4
• Cover lesions with waterproof bandages if water exposure unavoidable; avoid sharing towels, clothing, or personal items 1

---

Immunocompromised Patients

Multiple large lesions with minimal inflammation should immediately prompt consideration of immunocompromised state, and these patients require more aggressive treatment with possible dermatology referral. 1, 2

Key Differences in Immunocompromised Patients

Clinical Presentation:

• Atypical manifestations including giant, disseminated, necrotic, polypoidal, nodular forms, pseudocysts, or abscesses 1
• Minimal inflammation and may lack classic umbilication 1
• Extensive and recalcitrant disease that persists for prolonged periods 3
• Consider cryptococcal infection as differential diagnosis in atypical presentations 1

Treatment Approach:

• Physical removal methods remain first-line 2
• Consider dermatology referral for extensive disease or examination of suspicious lesions 1, 2
• Screen for immunocompromised state if extensive or recalcitrant disease present 1
• Alternative agents mentioned in European guidelines include cidofovir, imiquimod, or interferon for severe recalcitrant lesions, though evidence quality varies 7

Follow-Up

• Follow-up not usually necessary unless conjunctivitis persists or new lesions develop 1, 2
• Exception: Immunocompromised patients may require closer monitoring due to recalcitrant nature 1

Common Pitfalls to Avoid

• Missing nascent lesions during initial treatment is a frequent cause of recurrence 1
• Neglecting periocular lesions can lead to persistent conjunctivitis and ocular complications 1
• Using imiquimod based on outdated information—FDA label explicitly states studies failed to demonstrate efficacy 5
• Failing to recognize immunocompromised state when multiple large lesions present with minimal inflammation 1, 2